Back to search results

Using E-Nose Technology for Malignant Pleural Mesothelioma Treatment Response

This study is testing a new technology called E-Nose, or "breathprinting," to see how well it can measure your body's response to standard treatment for malignant pleural mesothelioma (MPM). Researchers will use the E-Nose to collect breath samples over time as you receive your usual MPM treatment. They will compare these breathprints to changes seen in your standard imaging scans (like CT or PET/CT) and to certain markers in your blood. The goal is to see if E-Nose can help understand how your treatment is working. This study plans to include 20 participants aged 30-85 who have been recently diagnosed with MPM and have no history of other specific cancers.

Study design
This is an interventional study with a planned enrollment of 20 participants. The phase of the study is not specified.
What's involved
You would have E-Nose breath tests at the start of the study and at follow-up visits. Research blood tests will also be taken at the start and during your first three standard follow-up visits.
Compensation
Not stated in the trial record.
Follow-up
Changes in specific breath markers will be measured for up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Recruiting
NAAges 30–85InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~20 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:E-Nose testingResearch blood

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change of MPMspecific VOCs
Measured over up to 1 year

Conditions

Malignant Pleural Mesothelioma

Explore related trials

Pleural Malignant Mesothelioma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Gaetano Rocco, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Gaetano Rocco, MD
[email protected]
212-639-3478
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 30-85 years
No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
Recent diagnosis of MPM
Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Exclusion

Aged \<30 or \>85 years at the first outpatient visit
History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

What this trial measures

  • Change of MPMspecific VOCsup to 1 year

    compared with imaging (using RECIST 1.1 and mRECIST).